相关实验视频
Updated: Jan 17, 2026

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
24.2K
tsRNA-25172 抑制阿尔多斯特产生阿尔多斯特腺瘤中的阿尔多斯特分泌
Qiwei Fan1,2,3, Liqing Liu4, Zhihua Jiang1,2,3
1Department of Endocrinology and Metabolism, First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Endocrine connections
|September 16, 2025
概括
转移RNA衍生小RNAs (tsRNAs) 在阿尔多素产生腺瘤 (APAs) 中起着关键作用. 下调的tsRNA-25172抑制了阿尔多素合成和CYP11B2的表达,为APAs提供了潜在的治疗标.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 产生阿尔多的腺瘤 (APA) 的特点是过度分泌阿尔多.
- 转移RNA衍生小RNAs (tsRNAs) 在阿尔多和APAs合成中的功能尚不清楚.
- tsRNAs是参与各种生物过程的新型非编码RNA.
研究的目的:
- 研究tsRNAs在APAs病理生理学中的作用.
- 与正常组织相比,在APA中识别差异表达的小RNA,包括tsRNA.
- 为了评估特定的tsRNAs对阿尔多斯特合成的调节作用.
主要方法:
- 免疫组织化学评估阿尔多素合成酶 (CYP11B2) 的表达.
- 小RNA测序以识别差异表达的miRNA,piRNA和tsRNA.
- 定量实时PCR (qRT-PCR),CCK-8测定和ELISA用于评估NCI-H295R细胞中的tsRNA功能.
主要成果:
- 在APA组织中观察到CYP11B2表达的增加.
- 在上腺皮层腺瘤 (ACA) 和正常组织之间确定了159个差异表达的tsRNA.
- 下调的tsRNA-25172显著抑制了阿尔多和皮质醇水平,并在NCI-H295R细胞中抑制了CYP11B2和TGM2的表达.
结论:
- tsRNA-25172在APA中调节阿尔多素合成中起着至关重要的作用.
- 失调的tsRNA与参与APA病变发生的途径有关.
- tsRNA-25172代表了APAs的一个潜在的新疗法标.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.4K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.4K
Antihypertensive Drugs: Potassium-Sparing Diuretics
2.2K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.2K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K

